YOLFTbeta
69

Andros Pharmaceuticals Co.,Ltd

6917 · TWO · Healthcare / Biotechnology

32.00TWD+0.10 (+0.31%)

Price History

Full chart

Market Stats

Previous Close31.90
Open31.70
Day Range31.30 – 33.35
52-Week Range20.00 – 45.95
Volume188.53K
Market Cap2.11B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.64
Dividend Yield0.00%
50-Day Avg33.49
200-Day Avg29.66

About

Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies. The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anesthetic that is in Phase I/II clinical trial for treatment of Osteoarthritis; and siRNA, an anti-sense oligonucleotide and DNA candidate. Its preclinical phase products are APC310 and APC501 for anesthesia to intravenous catheter placement and venipuncture; and APC401, a special emulsified solution for anesthesia of post-surgery pain. The company offers LALP cream for dermal analgesic applications; iMinos solution for Alopecia Androgenetica; and T4 endonuclease V. Andros Pharmaceuticals Co.,Ltd was founded in 2008 and is based in Zhubei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMing-Wen Lee
  • HeadquartersNo. 22, Shengyi Road, Zhubei, Taiwan, 30261, Taiwan
  • Websitehttps://www.andros.com.tw

Leadership

  • Ming-Wen LeeManagerial Officer & Director

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-3.27M13.31M1.71M805.00K203.00K5.55M
Growth (%)--+307.37%-87.13%-53.01%-74.78%+2633.00%
Cost of Revenue-892.00K4.72M747.00K492.00K193.00K3.75M
Gross Profit-2.38M8.59M966.00K313.00K10.00K1.80M
Gross Margin-72.71%64.55%56.39%38.88%4.93%32.44%
Operating Expense-44.82M45.20M41.68M74.02M89.62M77.44M
Operating Income-60.50M-42.44M-36.61M-40.71M-73.71M-89.61M-75.64M
Operating Margin--1298.68%-274.98%-2376.59%-9156.52%-44142.86%-1363.30%
EBITDA-60.50M-27.84M-29.74M-34.35M-61.50M-71.65M-46.49M
EBITDA Margin--851.96%-223.36%-2005.20%-7639.75%-35294.09%-837.96%
Net Income--35.89M-37.13M-41.18M-68.16M-78.28M-53.78M
Net Income Margin--1098.13%-278.92%-2403.74%-8466.96%-38561.08%-969.29%
R&D-36.31M32.54M35.57M56.86M71.76M58.17M
R&D as % of Total Revenue-1111.11%244.41%2076.71%7063.48%35348.77%1048.56%
Interest Expense541.00K559.00K500.00K464.00K440.00K341.00K271.00K
Interest Expense % of Total Revenue-17.11%3.76%27.09%54.66%167.98%4.88%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets186.78M153.35M120.27M329.60M529.15M441.48M558.97M
Total Liabilities59.89M62.99M51.60M50.12M58.04M47.31M43.25M
Total Equity126.89M90.36M68.66M279.48M471.11M394.17M515.72M
Cash22.76M13.80M14.63M88.19M269.01M38.85M53.76M
Total Debt43.36M38.79M34.56M31.25M27.12M22.03M-
Net Debt20.60M25.00M19.93M-56.94M-241.89M-16.82M-

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-52.98M-26.75M-35.87M-35.76M-46.64M-78.90M-45.45M
Investing Cash Flow35.28M23.00M25.90M-137.79M-27.33M-147.51M-
Financing Cash Flow-101.00K-4.57M9.23M247.12M255.01M-5.10M-
Capital Expenditure1.16M2.09M046.00K582.00K4.52M990.00K
Free Cash Flow-54.14M-28.84M-35.87M-35.80M-47.22M-83.42M-46.44M
FCF to OCF102.19%107.83%100.00%100.13%101.25%105.73%102.18%

Key Statistics & Ratios

Market Cap2.11B
Enterprise Value1.88B
Trailing P/E0.00
Forward P/E0.00
Price / Sales175.29
Price / Book4.53
EPS-0.64
Revenue (TTM)0
Gross Profit (TTM)0
Profit Margin0.00%
Operating Margin0.00%
Return on Equity0.00%
Return on Assets0.00%
Shares Outstanding61.27M
Shares Float0
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%